VolitionRx announced that its new lateral flow finger-prick prototype for Nu.Q® NETs, designed for rapid sepsis detection, showed high correlation with its established automated laboratory test. This development significantly expands the potential market for their technology by enabling point-of-care testing and access to underserved regions, potentially boosting future revenue streams.
VolitionRx has announced a significant breakthrough with its lateral flow finger-prick prototype for Nu.Q® NETs, demonstrating high correlation with its existing automated test for sepsis detection. This is a major development because it allows for rapid, point-of-care testing, moving beyond centralized labs and opening up vast new markets, particularly in regions with limited infrastructure. For traders, this presents a long-term opportunity for VNRX as it expands its total addressable market and potential for commercialization, especially through NGO partnerships. The short-term impact could be positive sentiment and increased investor interest due to the 'game-changer' potential in critical care and low-income countries.